Autolus Therapeutics plc (AUTL)
Nasdaq · Healthcare · Biotechnology
$1.83+2.81%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $487M
- 52-week range
- $1.18 – $2.58
- 52-week change
- +14.10%
- EPS (trailing)
- −$1.06
- Analyst rating
- 1.1 Strong buy
- Next earnings
- Nov 16, 2026
Fiscal year to Dec 2025
- Revenue
- $75.4M (+644.94%)
- Net income
- −$288M
- Operating margin
- −358.9%
- Diluted EPS
- −$1.08
- Free cash flow
- −$303M
From the company’s annual report on SEC EDGAR.
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Headquarters: London, United Kingdom · 752 employees · autolus.com